New Therapies and Biomarkers for Chagas Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

450

Participants

Timeline

Start Date

December 18, 2019

Primary Completion Date

May 29, 2024

Study Completion Date

May 31, 2024

Conditions
Trypanosoma Cruzi InfectionChagas Disease
Interventions
DRUG

Benznidazole

50 mg and 100 mg tablet taken orally

DRUG

Nifurtimox

120 mg tablet taken orally

Trial Locations (3)

Unknown

Platform for the Comprehensive Care of Patients with Chagas Disease, Cochabamba

Platform for the Comprehensive Care of Patients with Chagas Disease, Tarija

Platform for the Comprehensive Care of Patients with Chagas Disease, Sucre

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Fundación Ciencia y Estudios Aplicados para el Desarrollo en Salud y Medio Ambiente (CEADES)

UNKNOWN

collaborator

Barcelona Institute for Global Health

OTHER

collaborator

Institute of Parasitology and Biomedicine Lopez Neyra

UNKNOWN

collaborator

U.S. Food and Drug Administration (FDA)

UNKNOWN

collaborator

Drugs for Neglected Diseases

OTHER

collaborator

Mundo Sano Foundation

OTHER

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

University of Texas, El Paso

OTHER